Clinical Trials
17 trialsNCT07428993 2026-05-19
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06059391 2026-03-10
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 2 Recruiting
NCT06381830 2024-04-24
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01045460 2021-04-09
aMILs
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01329900 2020-07-08
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00651937 2020-01-14
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01174082 2018-06-01
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00984165 2018-05-02
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01547806 2018-03-07
Collection of Transplant Stem Cells for Plasma Cell Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02433483 2017-11-01
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT00499343 2013-08-02
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00968396 2013-04-05
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00067639 2012-08-01
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated